Pharmacogenomic testing is becoming more common in India, as doctors recognize its potential to personalize treatment based on genetic information. A recent case involved a patient whose genetic report revealed a variant in the MTHFR gene, leading to a successful treatment adjustment. Hospitals such as AIIMS and Fortis are beginning to incorporate these tests into their practices, particularly for patients at risk of adverse drug reactions. The Mira One panel from PreventiveHealth.ai aims to simplify the testing process by combining various assessments into one. Despite the promising growth of the genomic testing market, valued at about USD 550 million, challenges such as high costs (ranging from ₹15,000 to over ₹50,000) and a lack of awareness hinder widespread adoption. Doctors emphasize the importance of using these tests judiciously, particularly for patients with chronic conditions or strong family histories of disease. As patients increasingly arrive with genetic reports, the medical community faces the challenge of integrating this information into clinical practice.